Swaza develops a nanotechnology platform for oxygen delivery via non-invasive nanofluid breathing aids to treat respiratory distress. This technology enables dynamic gas exchange directly through compromised lung tissue, bypassing the need for invasive ventilation. The platform aims to improve outcomes for patients with conditions like COPD and IPF through superior topical oxygen delivery.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of delivering supplemental oxygen, such as oxygen tanks and ventilators, can be invasive, expensive, and require specialized equipment and trained personnel. This limits accessibility and can delay treatment for patients experiencing respiratory distress.
Solution
Swaza is developing a non-invasive nanofluid breathing aid designed to enhance gas exchange at the lung surface, increasing blood oxygen levels without the need for traditional oxygen delivery systems. The company's nanotechnology platform also supports the development of regenerative biomaterials for topical oxygen delivery, addressing needs in wound, burn, and trauma care. Swaza's approach offers a potentially safer and more accessible alternative to mechanical ventilation, with the goal of redefining the standard of care for respiratory distress. The nanofluid is designed to be simple to administer and stable at room temperature.
Target Audience
The primary target audience includes healthcare providers and patients in need of respiratory support, as well as those requiring advanced wound and tissue regeneration treatments.
Features
- Non-invasive nanofluid breathing aid for enhanced gas exchange
- Nanotechnology platform for regenerative biomaterials
- Topical oxygen delivery for wound, burn, and trauma care
- Safe ingredients
- Simple administration
- Room temperature stability